|By Business Wire||
|December 1, 2016 02:00 PM EST|
Ensysce Biosciences is pleased to announce the treatment of the first two patients with PF614, a two-step extended-release oxycodone prodrug designed to have abuse deterrent properties that limit its use to oral administration. The trial “A Phase 1, Single-Center, Dose-Escalation Study to Determine the Safety and Pharmacokinetics of a Single Oral Dose of PF614 in Healthy Subjects Compared to OxyContin®” is being conducted by Dr. Daniel Dickerson, MD, PhD, of PRA Health Sciences, Lenexa KS. This single ascending dose (SAD) study will treat up to 6 cohorts of 8 healthy male and/or female subjects randomized to take PF614 or OxyContin to evaluate safety and the pharmacokinetic profile of PF614 as compared to OxyContin.
PF614 is a trypsin-activated BIO-MD™ extended-release oxycodone prodrug with inherent abuse deterrence since it is pharmacologically and chemically inert until activation by pancreatic trypsin. The initial activation is followed by a second non-enzymatic cyclization and cleavage, producing free oxycodone and providing PF614 with extended release characteristics. Ensysce’s product pipeline includes immediate-release (IR) or extended-release (ER) prodrugs with timed activation of opioids and stimulants that present challenges for duration of action and abuse-deterrence. Additionally, Ensysce’s combination MPAR™ products combine the BIO-MD™ prodrugs with trypsin inhibitors, providing overdose protection. The MPAR™ technology has been demonstrated with PF329, an extended-release hydromorphone prodrug in a Phase 1 clinical study. Ensysce prodrugs are contrasted from current and emerging opioid technologies in that they do not require elaborate formulation to confer parenteral and nasal abuse-deterrence.
“Ensysce is pleased to bring PF614 into clinical development. We are focused on continuing to develop our opioid pipeline designed to significantly reduce abuse potential,” said Dr. Lynn Kirkpatrick, CEO, Ensysce Biosciences. “Our prodrug approach, BIO-MD™ is well differentiated from the formulation alterations that have been marketed for these products. BIO-MD™ and the combination MPAR™ overdose protection products are unique in the field.”
About Ensysce Biosciences:
Ensysce Biosciences, San Diego CA, is an integrated drug delivery company for both small and large molecules, using prodrug technology and single walled carbon nanotubes respectively. The BIO-MDTM prodrug abuse deterrent and MPAR™ overdose resistant pain platforms, with worldwide intellectual patent protection, eliminate the ability to abuse opioid products by the non-oral route, the fastest growing drug problem in the US that leads to billions in healthcare costs annually. This Phase 1 clinical trial for the BIO-MDTM abuse deterrent oxycodone prodrug, PF614 will provide data beginning at the end of 2016.
Dec. 4, 2016 04:45 AM EST Reads: 4,930
Dec. 4, 2016 04:30 AM EST Reads: 818
Dec. 4, 2016 04:30 AM EST Reads: 1,540
Dec. 4, 2016 04:00 AM EST Reads: 6,219
Dec. 4, 2016 04:00 AM EST Reads: 4,937
Dec. 4, 2016 03:45 AM EST Reads: 1,544
Dec. 4, 2016 02:15 AM EST Reads: 853
Dec. 4, 2016 02:00 AM EST Reads: 3,782
Dec. 4, 2016 12:30 AM EST Reads: 1,783
Dec. 3, 2016 11:00 PM EST Reads: 4,152
Dec. 3, 2016 11:00 PM EST Reads: 960
Dec. 3, 2016 09:30 PM EST Reads: 1,773
Dec. 3, 2016 09:30 PM EST Reads: 1,611
In his session at 19th Cloud Expo, Claude Remillard, Principal Program Manager in Developer Division at Microsoft, contrasted how his team used config as code and immutable patterns for continuous delivery of microservices and apps to the cloud. He showed how the immutable patterns helps developers do away with most of the complexity of config as code-enabling scenarios such as rollback, zero downtime upgrades with far greater simplicity. He also demoed building immutable pipelines in the cloud ...
Dec. 3, 2016 08:00 PM EST Reads: 1,748
The cloud competition for database hosts is fierce. How do you evaluate a cloud provider for your database platform? In his session at 18th Cloud Expo, Chris Presley, a Solutions Architect at Pythian, gave users a checklist of considerations when choosing a provider. Chris Presley is a Solutions Architect at Pythian. He loves order – making him a premier Microsoft SQL Server expert. Not only has he programmed and administered SQL Server, but he has also shared his expertise and passion with b...
Dec. 3, 2016 08:00 PM EST Reads: 3,958